Novavax hires vp of process development

Dr Erica Shane takes the role at the US biopharmaceutical firm

Novavax, a US-based clinical stage biopharmaceutical firm, has appointed Erica Shane, as vice president of process development.

Prior to joining Novavax, Shane was senior director of BioProcess Engineering at MedImmune. In this position, she was responsible for technology transfer to clinical and commercial sites as well as scale-up of cell culture and purification processes.

Shane joined the purification department in 1994 and spent 12 years developing clinical and commercial purification processes.

Prior to joining MedImmune, she held positions at DNX Corporation and American Cyanamid.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Zika outbreak gives rise to global fears

Zika may not be a new virus but its newly confirmed ability to cause foetal brain abnormalities makes the search for a treatment or a vaccine a high priority. Dr Sarah Houlton looks at the latest initiatives
Research & Development

Novavax vaccine candidate produces immune response against deadly virus

Study by University of Maryland School of Medicine highlights potential effective means for preventing MERS-CoV
Research & Development

Novavax, CPL Biologicals and ICGEB to develop malaria vaccine

Will combine Novavax VLP vaccine technology with CPLB manufacturing and ICGEB research capabilities
Manufacturing

Novavax signs long-term lease on vaccine plant

Will relocate corporate hq to same campus in Gaithersburg
Research & Development

US HHS awards influenza contracts worth US$215m

Novavax and VaxInnate to develop VLP and recombinant influenza vaccines, respectively
Regulatory

FDA clears Novavax RSV vaccine candidate for early stage trial

Novavax resolves question about chemistry, manufacturing and controls
Research & Development

Novavax RSV vaccine ‘safe and well tolerated’

Firm ready to advance towards human clinical trials
Subscribe now